Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 43 of the 45 references it cites were found in a registry or an index; 33 of the 49 sources its claims cite were checked for support.

New drugs for the treatment of obesity: do we need approaches to preserve muscle mass?

Open access
Ryan, Donna H. · 2025 · Reviews in Endocrine and Metabolic Disorders

Abstract

The development of drugs targeting Nutrient Stimulated Hormone receptors has ushered in a dramatic change in our approach to weight management because of their ability to achieve weight losses of 10%, 20%, even 30% in significant numbers of patients. Additionally, disease modifying properties of these medications are compelling. Indications now include cardiovascular risk reduction, obstructive sleep apnea and diabetes management, and emerging evidence supports efficacy for heart failure and chronic kidney disease. These medications would need to be taken long term and the population being treated will be older than the traditional weight management patient. Emerging evidence cautions that the loss of excessive lean mass with some of the newer medications may be problematic. This is not a concern for most patients who will need the medications, but it is a concern in an older population, since loss of muscle and bone accelerates and progresses past age 60. Of weight lost with semaglutide, approximately 45% is from lean mass, while with tirzepatide, it is 25%. Going forward, combining another NuSH such as glucagon or amylin with the GLP-1 receptor agonists may lessen loss of lean mass. Another approach under study is the use of MAPi - myostatin-activin pathway inhibitors. Promising results with bimagrumab are spurring investigaton in this area. For the full potential of disease modification to be achieved, it's a given that we must demonstrate safe, long term body composition improvement when the new medications are deployed, especially in the older population. This narrative review discusses the justification for focus on lean mass preservation and reviews the status of relevant drugs in development.

Overview

CoChat Summary

TL;DR

This narrative review argues that highly effective NuSH-based obesity drugs (semaglutide, tirzepatide) produce major weight loss and disease-modifying benefits but also raise concern about excessive lean-mass loss, especially in older adults. It reviews emerging strategies—NuSH combinations, myostatin-activin pathway inhibitors, and selective androgen receptor modulators—that may preserve muscle during weight loss.

Key findings

  • Semaglutide and tirzepatide produce large weight reductions: in STEP 1, semaglutide gave −14.9% vs −2.4% for placebo at week 68; in SURMOUNT-1, tirzepatide 5, 10, and 15 mg gave −15.0%, −18.5%, and −20.9% vs −2.4% for placebo at week 72. More patients achieved 10%/15%/20% weight loss with tirzepatide (90.1%/78.2%/62.9%) than semaglutide (74.8%/54.8%/34.8%).
  • Body-composition substudies indicate differential lean loss: approximately 45% of weight lost with semaglutide was lean mass, versus 25.7% with tirzepatide, despite greater overall weight loss with tirzepatide. The review states that no studies have yet evaluated bone and muscle mass with these drugs; DEXA reports only lean and fat compartments.
  • Long-term use appears necessary: in the STEP 1 extension, after withdrawal, net weight losses at week 120 were −5.6% for semaglutide and −0.1% for placebo; STEP 4 and SURMOUNT 4 showed weight regain and recidivism of health benefits after stopping.
  • Muscle-preservation candidates show early signals: in 168 older adults with overweight/obesity receiving semaglutide, enobosarm reduced mean percentage lean-mass loss (−1.2% vs −4.1% for placebo) and loss of 10% Stair Climb Power (19.4% vs 42.6%). In a 48-week bimagrumab study (n=77), fat mass fell −20.5% vs −0.5% for placebo, lean mass rose +3.6% vs −0.8%, and A1c fell −0.76% vs −0.04%.

Methods

  • Narrative review of current efficacy and safety profiles of NuSH-derived obesity medications, including GLP-1 receptor and GIP receptor agonists, and their disease-modifying attributes.
  • Discusses potential lean-mass sparing by targeting GIP, amylin, and glucagon, and reviews myostatin-activin pathway inhibitors (MAPi) and selective androgen receptor modulators (SARM).
  • Evidence is drawn from cited phase 3 trials, body-composition substudies, and selected press releases/registry entries; no new primary data or systematic search is reported.

Limitations

  • The paper states that body-composition effects of semaglutide and tirzepatide have not been extensively studied, that no studies have evaluated bone and muscle mass with these drugs, and that more studies with greater definition of muscle and bone effects are needed.
  • The paper states that SELECT fracture findings were inconclusive and require additional data, and that evidence for SARM use is sparse.
  • Evident from the text: this is a narrative review relying on cited trials, unpublished top-line results, and web links; some relevant data are not yet published (e.g., bimagrumab plus semaglutide results, retatrutide body-composition data).

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1007/s11154-025-09967-4

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Phase 2 Study of Bimagrumab in Individuals with Obesity and Type 2 Diabetes [44]. In this 48-week study, adults with type 2 diabetes, body mass index between 28 and 40, and glycated hemoglobin (HbA1c) levels between 6.5% and 10.0% were randomly assigned to placebo or control at 9 US and UK sites. At 49 weeks, those assigned to bimagrumab had lost − 20.5% fat mass, gained + 3.6% lean mass and reduced HbA1c by 0.76 percentage points (P < 0.001 compared to placebo for all)
Fig. 1 Phase 2 Study of Bimagrumab in Individuals with Obesity and Type 2 Diabetes [44]. In this 48-week study, adults with type 2 diabetes, body mass index between 28 and 40, and glycated hemoglobin (HbA1c) levels between 6.5% and 10.0% were randomly assigned to placebo or control at 9 US and UK sites. At 49 weeks, those assigned to bimagrumab had lost − 20.5% fat mass, gained + 3.6% lean mass and reduced HbA1c by 0.76 percentage points (P < 0.001 compared to placebo for all)CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

25 Valid · 2 Not valid · 12 Not checked · 10 Own results and interpretations

25 more claims · 10 with their cited sources checked

Create a free account to see all 49 claims and every source verdict.

See all claims — free account
  • Probably not a substantial claim. 5
  • It may state two separate claims as one. 14
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 45 references

Research works printed but not linked: 3

  1. le Roux CW, Steen O, Lucas KJ, Startseva E, Unseid Am Hennige AM. Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. Lancet Diabetes Endocrinol. 2024;12(3):162–73. · DOI · Paper page
  2. Jastreboff AM, Kaplan LM, Frias JP, et al. Triple-hormone-receptor agonist retatrutide for obesity - a phase 2 trial. N Engl J Med. 2023;389(6):514–26. · DOI · Paper page
  3. Burmeister MA and Fincher TK. Recreational use of selective androgen receptor modulators. US Pharm. 2020; 45(60):15-1.

Cited by

See all 34

Metadata

Authors
Ryan, D. H.
Affiliations
Pennington Biomedical Research Center (US)
Corresponding author
Ryan, Donna H.
Venue
Reviews in Endocrine and Metabolic Disorders
Published
2025-05-05
Volume
26
Issue
5
Pages
805-813
ISSN
  • 1389-9155 (ISSN-L)
  • 1573-2606
OpenAlex
W4410069635
Cited by
34
References
45
Citations by year
2026: 17 · 2025: 17
FWCI
4.56
Type
journal article
Language
en
Open access
Licence
Locations
  • Reviews in Endocrine and Metabolic Disorders (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
obesity treatment, lean mass preservation, GLP-1 receptor agonists, semaglutide, tirzepatide, glucagon, amylin, bimagrumab, body composition, weight loss, older adults, disease modification, cardiovascular risk reduction, obstructive sleep apnea, diabetes management, heart failure, chronic kidney disease
MeSH terms
Humans, Obesity, Muscle, Skeletal, Anti-Obesity Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: New drugs for the treatment of obesity: do we need approaches to preserve muscle mass? https://app.cochat.ai/papers/10.1007/s11154-025-09967-4
The paper
Ryan, D. H. (2025). New drugs for the treatment of obesity: do we need approaches to preserve muscle mass? Reviews in Endocrine and Metabolic Disorders. https://doi.org/10.1007/s11154-025-09967-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.